This move is archived. Current quotes and coverage live on the stock page.
Get MDNA alerts:
Medicenna Therapeutics Corp is seeing a noticeable increase in its stock price, reflecting positive investor sentiment.
Medicenna Therapeutics Corp (MDNA.TO) is up today, gaining 2.90% and closing at CA$0.35. This rise comes as the company makes strides in its clinical programs and expands its market presence.
Investor takeaway: Investors are responding positively to Medicenna's recent announcements and clinical milestones, indicating growing confidence in its pipeline and market strategy.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$37.84M
52W high
$1.97
52W low
$0.34
1W change
-10.87%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 680.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+680.5% Upside
Current Price
C$0.41
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
56.4%
Annualized
90-Day Vol
69.0%
Annualized
Trend (90d)
-15.1%
Annualized drift
90d Mean
C$0.39
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.40 | C$0.33 – C$0.49 |
| 60 trading days | C$0.40 | C$0.30 – C$0.52 |
| 90 trading days | C$0.39 | C$0.28 – C$0.54 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Medicenna's Market Cap Hits CA$31.84 Million
With a market cap of CA$31.84 million, Medicenna is still a small player in the biotech sector. This highlights the need for continued progress in its clinical trials to support its valuation.
Bull case
The recent increase in Medicenna's stock may be linked to its upcoming presentation of clinical data. This could boost investor confidence in its lead programs and attract new investments.
Bear case
Despite the positive movement, the company faces challenges, including the absence of immediate financial results and a market cap of only CA$31.84 million. These factors may raise concerns about its long-term sustainability.
Recent Performance
Advertisement
Medicenna's stock is on the rise today, reflecting a 2.90% increase. This uptick is a good sign for investors, especially as the company gears up for significant clinical data presentations scheduled for December.
Market Reactions
Investor sentiment seems to be strengthened by Medicenna's strategic announcements, including the upcoming ESMO Immuno-Oncology Congress presentation. Such events often lead to increased interest and investment in biotech firms.
Looking Ahead
As Medicenna continues to develop its clinical programs, keeping investor confidence high will be essential. The stock's performance today might indicate a broader trend if the company can meet its upcoming milestones.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
